A Phase III Study of TMC435 in Genotype 1, Hepatitis C-infected Participants Who Failed to Respond to Previous IFN-based Therapy

NCT01288209 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

106

Enrollment

INDUSTRY

Sponsor class

Conditions

Hepatitis C, Chronic

Interventions

DRUG: TMC435
DRUG: Peginterferon alfa-2a (PegIFNα-2a )
DRUG: Ribavirin (RBV)

Sponsor

Janssen Pharmaceutical K.K.